Session 1 (5:30pm-7pm)
Digital health & Biomarkers
• State of the art of telemedicine trial results - J Cleland / UK
• Using biomarkers in HF - update 2020 - J Januzzi / USA
• Managing HF patients in COVID-19 times - Y Zhang / CHI
• Big data and AI approaches – what is on the horizon? - V Mahajan / IND

Session 2 (8:30pm-10pm)
Basics in HF: Epidemiology, clinical settings, treatments
• Treatment algorithm of HFrEF - J Ezekowitz / CAN
• HFrEF vs HFmEF vs HFpEF – similarities and differences - P Seferovic / SRB
• Diagnostic approaches in HFpEF - C Lam / SING
• Treatment approaches in HFpEF - S Solomon / USA

Session 3 (5:30pm-7pm)
Update on acute HF
• Management of AHF – State of the art – G Filippato / GR
• Post MI acute heart failure - A Hernandez / USA
• Inflammatory cardiomyopathy and viral myocarditis - B Bozkurt / USA
• Cardiogenic shock - O Chioncel / ROM

Session 4 (5:30pm-7pm)
State of the art management of chronic HF
• RAASi/ARNi, MRAs and beta blockers - F Zannad / FRA
• SGLT2 inhibitors - M Packer / USA
• Vericiguat, the new data - B Pieske / GER
• Managing anticoagulation in HF - G Rosano / ITA

Session 5 (5:30pm-7pm)
Treat HFpEF: Is clinical practice the same around the World?
• SOBOTA-HF study: HF prevalence in the general population - M Mitja Lainscak / SVN
• Data from the Swedish HF Registry: Lower socioeconomic status predicts higher mortality & morbidity – - W Abraham / USA
• EMPERIAL Trials update - W, Abraham / USA
• Data from the EMPA-REG Outcomes trial – S. Anker / GER
• AMBER trial results in the pre-specified subgroup with heart failure - P. Rossignol / FR

Session 6 (5:30pm-7pm)
HFrEF vs HFrEF vs HFpEF – similarities and differences - P Seferovic / SRB
• Diagnostic approaches in HFpEF - C Lam / SING
• Treatment approaches in HFpEF - S Solomon / USA

Session 7 (5:30pm-7pm)
Update on acute HF
• Management of AHF – State of the art – G Filippato / GR
• Post MI acute heart failure - A Hernandez / USA
• Inflammatory cardiomyopathy and viral myocarditis - B Bozkurt / USA
• Cardiogenic shock - O Chioncel / ROM

Keynote Lecture (7:00pm-7:25pm)
Gold-standard treatment of HFrEF in 2020 – J. McMurray / UK

7pm-8:30pm: INDUSTRY SESSIONS
SGLT2 INHIBITORS – THE NEW HF THERAPIES ON THE BLOCK (BOEHRINGER, LILLY)

7:25pm - 8:30pm: INDUSTRY SESSIONS
TREATING HFpEF: IS CLINICAL PRACTICE THE SAME AROUND THE WORLD? (AMGEN, CYTOKINETICS, SERVIER)

7pm-8:30pm: INDUSTRY SESSIONS
GETTING TO THE HEART OF MANAGING HEART FAILURE (AMGEN, CYTOKINETICS, SERVIER)

Session 8 (8:30pm-10pm)
Update on advanced HF, assist devices and heart transplantation
• Patient with very poor prognosis and very low EF - D Choi / KOR
• Mechanical circulatory support (MCS) - F Bader / UAE
• Heart transplantation vs destination LVAD - L Stevenson / USA
• Organising cardiac surgery and interventional care for HF in Covid times - M Metra / ITA

Session 11 (8:30pm-10pm)
Late-breaking abstracts (part 1)
• SOBOTA-HF study: HF prevalence in the general population - M Mitja Lainscak / SVN
• Data from the Swedish HF Registry: Lower socioeconomic status predicts higher mortality & morbidity – - W Abraham / USA
• EMPERIAL Trials update - W, Abraham / USA
• Data from the EMPA-REG Outcomes trial – S. Anker / GER
• AMBER trial results in the pre-specified subgroup with heart failure - P. Rossignol / FR

Session 12 (8:30pm-10pm)
Late-breaking abstracts (part 2)
• SOBOTA-HF study: HF prevalence in the general population - M Mitja Lainscak / SVN
• Data from the Swedish HF Registry: Lower socioeconomic status predicts higher mortality & morbidity – - W Abraham / USA
• EMPERIAL Trials update - W, Abraham / USA
• Data from the EMPA-REG Outcomes trial – S. Anker / GER
• AMBER trial results in the pre-specified subgroup with heart failure - P. Rossignol / FR

ESPACEHF.ORG
**Day 2**

### Session 9 (5:30pm-7pm)
**Difficult problems in HF**
- The patient with low blood pressure and poor renal function with acute HF - S. Matskeplishvili / RUS
- Elderly patient with mid-range EF and suspicion of amyloid - S. Zieroth / CAN
- Causes and management of heart failure in low resource settings - K. Sliwa / SA
- The patient with cancer and cardio-toxic chemotherapy - A. Lyon / UK

### Session 5 (5:30pm-7pm)
**Co-morbidities in HF (part 1)**
- Diabetes in HF - J. McMurray / UK
- Atrial Fibrillation - J. Atherton / AUS
- Managing obesity and cachexia - M. Abdelhamid / EGY
- Sleep Apnea - M. Boehm / GER

### Session 12 (5:30pm-7pm)
**DAPA HF one year on: what have you missed?**
- Effect of dapagliflozin on outpatient worsening in patients with HFrEF – J. McMurray / UK
- Benefit of dapagliflozin on first and repeat events in patients with HFrEF – P. Ponikowski / POL
- DAPA-HF: effect of dapagliflozin on renal outcomes in HFrEF – S. Solomon / USA
- Impact of dapagliflozin treatment on KCCQ – M. Kosiborod / USA
- Dapagliflozin and diuretic use in patients with HFrEF – A. Jackson / UK

### Session 10 (8:30pm-10pm)
**New drugs and devices for HF therapy**
- Omecamtiv Mecarbil for chronic HF - J. Teerlink / USA
- Devices for functional MR beyond Mitraclip - S. von Bardeleben / GER
- Devices for baroreflex stimulation - A. Coats / AUS
- More on new drugs and devices on the horizon – S. Anker / GER

### Session 6 (8:30pm-10pm)
**Co-morbidities in HF (part 2)**
- CKD - C. Yancy / USA
- Hyperkalemia - J. Butler / USA
- ID with and without anaemia - P. Ponikowski / POL
- Exercise and managing frailty - S. Makita / JAP

### Session 3 (8:30pm-10pm)
**Valvular heart disease in HF**
- State of art for imaging for diagnosis of valvular disease and assessment of risk – F. Pinto / POR
- Aortic valve disease - A. Abizaid / Brazil
- Tricuspid disease – H. Sievert / GER
- Mitral valve disease - W. Abraham / USA

---

**THE 1ST GLOBAL WEB-CONFERENCE ON heart failure**

**July 11-14, 2020**

**Beijing**
GMT +8

**Athens**
GMT +3

**New York**
GMT -4
**Day 3**

**Session 7 (5:30pm-7pm)**
**Update on acute HF**
- Management of AHF – State of the art - G Filippatos / GR
- Post MI acute heart failure - A Hernandez / USA
- Inflammatory cardiomyopathy and viral myocarditis - B Bozkurt / USA
- Cardiogenic shock - O Chioncel / ROM

**Session 1 (5:30pm-7pm)**
**Digital health & Biomarkers**
- State of the art of telemedicine trial results - J Cleland / UK
- Using biomarkers in HF – update 2020 - J Januzzi / USA
- Managing HF patients in COVID-19 times - Y Zhang / CHI
- Big data and AI approaches – what is on the horizon? - V Mahajan / IND

**Session 4 (5:30pm-7pm)**
**State of the art management of chronic HF**
- RAASi/ARNI, MRAs and beta blockers - F Zannad / FRA
- SGLT2 inhibitors - M Packer / USA
- Vericiguat, the new data - B Pieske / GER
- Managing anticoagulation in HF - G Rosano / ITA

**Session 8 (8:30pm-10pm)**
**Update on advanced HF, assist devices and heart transplantation**
- Patient with very poor prognosis and very low EF - D Choi / KOR
- Mechanical circulatory support (MCS) - F Bader / UAE
- Heart transplantation vs destination LVAD - L Stevenson / USA
- Organising cardiac surgery and interventional care for HF in Covid times - M Metra / ITA

**Session 2 (8:30pm-10pm)**
**Basics in HF: Epidemiology, clinical settings, treatments**
- Treatment algorithm of HFrEF - J Ezekowitz / CAN
- HFrEF vs HFrEfrEF vs HFrEF – similarities and differences - P Seferovic / SRB
- Diagnostic approaches in HFrEF - C Lim / SING
- Treatment approaches in HFrEF - S Solomon / USA

**Session 13 (8:30pm-10pm)**
**Late-breaking abstracts (part 2)**
- Left ventricular EF & long-term mortality: Insights from the Ntl. Echocardiography Database of Australia - S. Stewart / AUS
- Structural heart disease and preserved ejection fraction: Insights from the Ntl. Echocardiography Database of Australia - D. Playford / AUS
- Observations from the RELIEVE-HF roll-in cohort - G. Stone / US
- A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and HF... - A. Coats / UK
- An update on the rEF vs MrEF vs pEF landscape — data from the HFA registry program. - L. Lund / SWE
Day 4

**Beijing**
GMT +8

Session 6 (5:30pm-7pm)
Co-morbidities in HF (part 2)
- CKD - C Yancy / USA
- Hyperkalemia - J Butler / USA
- ID with and without anaemia - P Ponikowski / POL
- Exercise and managing frailty - S Makita / JAP

Session 7pm-8:30pm
INDUSTRY SESSIONS
IMPROVING OUTCOMES IN HEART FAILURE - FOCUS ON GUIDELINE ADHERENCE AND COMORBIDITIES (MedEdGS, VIFOR)

**Athens**
GMT +3

Session 11 (5:30pm-7pm)
Late-breaking abstracts (part 3)
- The Telemedical Interventional Management in Heart Failure Trial 2 (TIM-HF2) - F Köhler / GER
- Voice analysis by a smartphone app to identify lung congestion in HF patients - A Amir / ISR
- ETIFIC multicenter randomized trial.
- J Oyanguren / SPA
- Phrenic nerve stimulation improves symptoms associated with central sleep apnoea in HF patients - L Hill / UK
- Results from MEMS-HF and the CardioMEMS US Post-Approval Study P Adamson / US

Session 7pm-8:30pm
INDUSTRY SESSIONS
GLOBAL CHALLENGES AND OPPORTUNITIES FOR HF DIAGNOSIS, TREATMENT AND RESEARCH (LISBON SCHOOL OF MEDICINE, UNIVERSITY OF LISBON AND CHARITE BERLIN IN COLLABORATION WITH THE WORLD HEART FEDERATION)

**New York**
GMT -4

Session 10 (5:30pm-7pm)
New drugs and devices for HF therapy
- Omecamtiv Mecarbil for chronic HF - J Teerlink / USA
- Devices for functional MR beyond Mitraclip - S von Bardeleben / GER
- Devices for baroreflex stimulation - A Coats / AUS
- More on new drugs and devices on the horizon - S Anker / GER

Session 7pm-8:30pm
INDUSTRY SESSIONS
GLOBAL CHALLENGES AND OPPORTUNITIES FOR HF DIAGNOSIS, TREATMENT AND RESEARCH (LISBON SCHOOL OF MEDICINE, UNIVERSITY OF LISBON AND CHARITE BERLIN IN COLLABORATION WITH THE WORLD HEART FEDERATION)

**Session 5 (8:30pm-10pm)**
Co-morbidities in HF (part 1)
- Diabetes in HF - I McMurray / UK
- Atrial Fibrillation - J Atherton / AUS
- Managing obesity and cachexia - M Abdelhamid / EGY
- Sleep Apnea - M Boehm / GER

**Session 3 (8:30pm-10pm)**
Valvular heart disease in HF
- State of art for imaging for diagnosis of valvular disease and assessment of risk - P Pinto / POR
- Aortic valve disease - A Abizaid / Brazil
- Tricuspid disease - H Sievert / GER
- Mitral valve disease - W Abraham / USA

**Session 9 (8:30pm-10pm)**
Difficult problems in HF
- The patient with low blood pressure and poor renal function with acute HF - S Matskeplishvili / RUS
- Elderly patient with mid-range EF and suspicion of amyloid - S Zieroth / CAN
- Causes and management of heart failure in low resource settings - K Siwa / SA
- The patient with cancer and cardiotoxic chemotherapy - A Lyon / UK

**Session 11 (8:30pm-10pm)**
Co-morbidities in HF (part 2)
- Diabetes in HF - I McMurray / UK
- Atrial Fibrillation - J Atherton / AUS
- Managing obesity and cachexia - M Abdelhamid / EGY
- Sleep Apnea - M Boehm / GER

**Session 6 (5:30pm-7pm)**
Co-morbidities in HF (part 2)
- CKD - C Yancy / USA
- Hyperkalemia - J Butler / USA
- ID with and without anaemia - P Ponikowski / POL
- Exercise and managing frailty - S Makita / JAP

**Session 7pm-8:30pm**
INDUSTRY SESSIONS
IMPROVING OUTCOMES IN HEART FAILURE - FOCUS ON GUIDELINE ADHERENCE AND COMORBIDITIES (MedEdGS, VIFOR)

**Session 7pm-8:30pm**
INDUSTRY SESSIONS
GLOBAL CHALLENGES AND OPPORTUNITIES FOR HF DIAGNOSIS, TREATMENT AND RESEARCH (LISBON SCHOOL OF MEDICINE, UNIVERSITY OF LISBON AND CHARITE BERLIN IN COLLABORATION WITH THE WORLD HEART FEDERATION)